Cargando…

Bioengineering strategies for the treatment of peripheral arterial disease

Peripheral arterial disease (PAD) is a progressive atherosclerotic disorder characterized by narrowing and occlusion of arteries supplying the lower extremities. Approximately 200 million people worldwide are affected by PAD. The current standard of operative care is open or endovascular revasculari...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Cui, Kitzerow, Oliver, Nie, Fujiao, Dai, Jingxuan, Liu, Xiaoyan, Carlson, Mark A., Casale, George P., Pipinos, Iraklis I., Li, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511653/
https://www.ncbi.nlm.nih.gov/pubmed/33005831
http://dx.doi.org/10.1016/j.bioactmat.2020.09.007
_version_ 1783585998658076672
author Li, Cui
Kitzerow, Oliver
Nie, Fujiao
Dai, Jingxuan
Liu, Xiaoyan
Carlson, Mark A.
Casale, George P.
Pipinos, Iraklis I.
Li, Xiaowei
author_facet Li, Cui
Kitzerow, Oliver
Nie, Fujiao
Dai, Jingxuan
Liu, Xiaoyan
Carlson, Mark A.
Casale, George P.
Pipinos, Iraklis I.
Li, Xiaowei
author_sort Li, Cui
collection PubMed
description Peripheral arterial disease (PAD) is a progressive atherosclerotic disorder characterized by narrowing and occlusion of arteries supplying the lower extremities. Approximately 200 million people worldwide are affected by PAD. The current standard of operative care is open or endovascular revascularization in which blood flow restoration is the goal. However, many patients are not appropriate candidates for these treatments and are subject to continuous ischemia of their lower limbs. Current research in the therapy of PAD involves developing modalities that induce angiogenesis, but the results of simple cell transplantation or growth factor delivery have been found to be relatively poor mainly due to difficulties in stem cell retention and survival and rapid diffusion and enzymolysis of growth factors following injection of these agents in the affected tissues. Biomaterials, including hydrogels, have the capability to protect stem cells during injection and to support cell survival. Hydrogels can also provide a sustained release of growth factors at the injection site. This review will focus on biomaterial systems currently being investigated as carriers for cell and growth factor delivery, and will also discuss biomaterials as a potential stand-alone method for the treatment of PAD. Finally, the challenges of development and use of biomaterials systems for PAD treatment will be reviewed.
format Online
Article
Text
id pubmed-7511653
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-75116532020-09-30 Bioengineering strategies for the treatment of peripheral arterial disease Li, Cui Kitzerow, Oliver Nie, Fujiao Dai, Jingxuan Liu, Xiaoyan Carlson, Mark A. Casale, George P. Pipinos, Iraklis I. Li, Xiaowei Bioact Mater Article Peripheral arterial disease (PAD) is a progressive atherosclerotic disorder characterized by narrowing and occlusion of arteries supplying the lower extremities. Approximately 200 million people worldwide are affected by PAD. The current standard of operative care is open or endovascular revascularization in which blood flow restoration is the goal. However, many patients are not appropriate candidates for these treatments and are subject to continuous ischemia of their lower limbs. Current research in the therapy of PAD involves developing modalities that induce angiogenesis, but the results of simple cell transplantation or growth factor delivery have been found to be relatively poor mainly due to difficulties in stem cell retention and survival and rapid diffusion and enzymolysis of growth factors following injection of these agents in the affected tissues. Biomaterials, including hydrogels, have the capability to protect stem cells during injection and to support cell survival. Hydrogels can also provide a sustained release of growth factors at the injection site. This review will focus on biomaterial systems currently being investigated as carriers for cell and growth factor delivery, and will also discuss biomaterials as a potential stand-alone method for the treatment of PAD. Finally, the challenges of development and use of biomaterials systems for PAD treatment will be reviewed. KeAi Publishing 2020-09-22 /pmc/articles/PMC7511653/ /pubmed/33005831 http://dx.doi.org/10.1016/j.bioactmat.2020.09.007 Text en © 2020 [The Author/The Authors] http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Li, Cui
Kitzerow, Oliver
Nie, Fujiao
Dai, Jingxuan
Liu, Xiaoyan
Carlson, Mark A.
Casale, George P.
Pipinos, Iraklis I.
Li, Xiaowei
Bioengineering strategies for the treatment of peripheral arterial disease
title Bioengineering strategies for the treatment of peripheral arterial disease
title_full Bioengineering strategies for the treatment of peripheral arterial disease
title_fullStr Bioengineering strategies for the treatment of peripheral arterial disease
title_full_unstemmed Bioengineering strategies for the treatment of peripheral arterial disease
title_short Bioengineering strategies for the treatment of peripheral arterial disease
title_sort bioengineering strategies for the treatment of peripheral arterial disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511653/
https://www.ncbi.nlm.nih.gov/pubmed/33005831
http://dx.doi.org/10.1016/j.bioactmat.2020.09.007
work_keys_str_mv AT licui bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT kitzerowoliver bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT niefujiao bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT daijingxuan bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT liuxiaoyan bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT carlsonmarka bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT casalegeorgep bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT pipinosiraklisi bioengineeringstrategiesforthetreatmentofperipheralarterialdisease
AT lixiaowei bioengineeringstrategiesforthetreatmentofperipheralarterialdisease